CoreWeave (CRWV) is rated Buy, favored for its larger scale, lower reliance on prepayment funding, and stronger cash flow, which reduce cash burn and improve return on invested capital compared to Nebius (NBIS), rated Sell. Although Nebius trades at a premium due to a clean balance sheet, rising capital expenditures and debt are expected to erode this advantage. Both companies face risks related to execution, funding, and energy costs, but CoreWeave's discounted valuation and superior EBITDA growth make it the preferred AI infrastructure investment. The analysis is based on fundamental financial data and aims to guide long-term investment decisions.
Equity markets continue to rise driven by optimism around AI, with companies like CoreWeave and Nebius posting strong quarterly results. However, credit markets are showing signs of increasing stress, particularly in private credit and commercial rea...
President Trump's executive order to separate the combined MMR vaccine into individual shots faces significant regulatory and manufacturing challenges, with FDA approval potentially taking up to 10 years. Merck and GSK, the only licensed producers of...
Nebius exceeded expectations in its Q2 earnings, driven by rapid growth in its cloud computing base and high demand for GPUs. The company raised its cloud capacity forecast for the current fiscal year by 25% to 5 GW, signaling strong expansion. Nebiu...
Nebius shares surged 34% following a quarterly report showing a 454% revenue increase to $582 million and a reduced loss per share of $0.12. This strong performance led several analysts, including those from Bank of America and Baird, to raise their ...
Nebius and CoreWeave reported strong Q2 2026 earnings driven by soaring AI compute demand. Nebius saw a 454% revenue jump to $582.3 million, with its AI Cloud segment nearly covering all revenue and showing significant profit gains. CoreWeave, larger...
